Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.

ABSTRACT:

Background

PRRT with [¹⁷⁷Lu]Lu-DOTA-TATE improves survival in advanced GEP-NETs, but fixed-activity dosing may result in undertreatment or unnecessary toxicity. Individualized dosimetry and tandem-PRRT with ⁹⁰Y/¹⁷⁷Lu have been proposed, but prospective randomized evidence is lacking.

Methods

DUONEN is an ongoing multicenter, randomized phase 3 trial (N = 92 planned; 56 analyzed) comparing standard fixed-activity [¹⁷⁷Lu]Lu-DOTA-TATE (arm A) with three dosimetry-guided regimens: arm B (¹⁷⁷Lu+⁹⁰Y, variable ⁹⁰Y); arm C (¹⁷⁷Lu+⁹⁰Y, variable ¹⁷⁷Lu); arm D (variable ¹⁷⁷Lu). Organ dosimetry was performed after each cycle, with per-cycle activity modifications to r

SUBMITTER: Kolodziej M 

PROVIDER: S-EPMC12702747 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature